Impact of frailty on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a nationwide cohort study.
Maxim GrymonprezMirko PetrovicTine L De BackerStephane SteurbautLies LahoussePublished in: European heart journal. Quality of care & clinical outcomes (2023)
Frailty was an independent risk factor of death. NOACs had better benefit-risk profiles than VKAs in patients with frailty, especially apixaban, followed by edoxaban.